Clinical Practice UpdatesAGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest These authors disclose the following: David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Russell D. Cohen serves on the speakers' bureau for Abbvie and Takeda. He is a consultant for Abbvie, BMS/Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, and UCB Pharma. He is principal investigator or has received grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. His spouse is on the Board of Directors at Aerpio Therapeutics, Novus Therapeutics (Board of Directors), and NantKwest. The remaining authors disclose no conflicts.